2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Transfusiones al final de la vida. Revisión de algunas consideraciones importantes Translated title: Transfusions at the end of life. Review of some important considerations

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN La trasfusión de hemoderivados se utiliza con más frecuencia en pacientes con neoplasias hematológicas que en pacientes con tumores sólidos, y de forma variable en el caso de pacientes terminales con otro tipo de patologías. La anemia y trombocitopenia son frecuentes en este grupo diverso de pacientes, que reciben tratamientos hasta el final de la vida, siendo la transfusión de componentes sanguíneos, como los glóbulos rojos o las plaquetas, una intervención necesaria para el alivio de síntomas y mejoras en el estado clínico. Sin embargo, en pacientes con enfermedad terminal, los síntomas son de origen multifactorial y los valores hematológicos no necesariamente se convierte en un criterio para transfundir. No obstante, la evidencia científica que apoya que las transfusiones mejoren significativamente los síntomas de los pacientes paliativos aún no es concluyente. A pesar de que la literatura define algunas indicaciones para transfundir las dificultades, empiezan en el contexto de la selección del tipo de transfusión, la cantidad de las mismas y el fin de vida. En la literatura científica se encuentran diferentes comunicaciones que relacionan las últimas unidades de hemoderivados administrados, previo a la muerte del paciente; sin embargo, poco se encuentra con relación a criterios uniformes que apoyen la decisión al final de la vida y la relación riesgo beneficio no es clara. Las trasfusiones sanguíneas, además de ser procedimientos comunes en la práctica clínica, son terapias que generan riesgos y costes considerables para el sistema, por lo que la búsqueda de opciones alternas se hace imperativo a la hora de evitar terapias innecesarias. Los pacientes con necesidades transfusionales al final de la vida generalmente tienen antecedente de enfermedad crónica conocida; es por esto por lo que la movilización de recursos individuales y familiares se convierte en el reto del personal asistencial, pues de esto va a depender en gran parte la forma como se afronta la situación y los vínculos que se generan, por lo que el abordaje debe realizarse de manera interdisciplinaria.

          Translated abstract

          ABSTRACT Transfusion of blood products is used more frequently in patients with hematological malignancies than in patients with solid tumors, and variably in the case of terminally ill patients with other types of pathologies. Anemia and thrombocytopenia are frequent in this diverse group of patients, who receive treatments until the end of life, the transfusion of blood components, such as red blood cells or platelets, being a necessary intervention for the relief of symptoms and improvements in condition. clinical. However, in terminally ill patients, symptoms are multifactorial in origin and hematological values do not necessarily become a criterion for transfusing, however, the scientific evidence supporting that transfusions significantly improve the symptoms of palliative patients has not yet is conclusive. Although the literature defines some indications for transfusing difficulties, they begin in the context of the selection of the type of transfusion, the amount of the transfusion, and the end of life. In the scientific literature there are different reports that list the last units of blood products administered, prior to the death of the patient; however, little is found in relation to uniform criteria that support the decision at the end of life and the risk benefit ratio is not clear. Blood transfusions, in addition to being common procedures in clinical practice, are therapies that generate considerable risks and costs for the system, so the search for alternative options becomes imperative when it comes to avoiding unnecessary therapies. Patients with end-of-life transfusion needs generally have a history of known chronic disease; It is for this reason that the mobilization of individual and family resources becomes the challenge for healthcare personnel, since this will largely depend on the way in which the situation is dealt with and the links that are generated, so the approach must be carried out in an interdisciplinary way.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Platelet transfusion: a clinical practice guideline from the AABB.

          The AABB (formerly, the American Association of Blood Banks) developed this guideline on appropriate use of platelet transfusion in adult patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.

            There is considerable uncertainty regarding the optimal haemoglobin threshold for the use of red blood cell (RBC) transfusions in anaemic patients. Blood is a scarce resource, and in some countries, transfusions are less safe than others because of a lack of testing for viral pathogens. Therefore, reducing the number and volume of transfusions would benefit patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Transfusion reactions: prevention, diagnosis, and treatment.

              Blood transfusion is one of the most common procedures in patients in hospital so it is imperative that clinicians are knowledgeable about appropriate blood product administration, as well as the signs, symptoms, and management of transfusion reactions. In this Review, we, an international panel, provide a synopsis of the pathophysiology, treatment, and management of each diagnostic category of transfusion reaction using evidence-based recommendations whenever available.
                Bookmark

                Author and article information

                Journal
                dolor
                Revista de la Sociedad Española del Dolor
                Rev. Soc. Esp. Dolor
                Inspira Network Group, S.L (Madrid, Madrid, Spain )
                1134-8046
                February 2021
                : 28
                : 1
                : 47-52
                Affiliations
                [1] Medellín orgnameUniversidad Pontificia Bolivariana Colombia
                [3] Medellín orgnameUniversidad Pontificia Bolivariana Colombia
                [2] Medellín orgnameUniversidad Pontificia Bolivariana Colombia
                Article
                S1134-80462021000200047 S1134-8046(21)02800100047
                10.20986/resed.2021.3831/2020
                48b2799f-d933-4a9c-900a-5dad88b786cd

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

                History
                : 30 June 2020
                : 04 March 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 42, Pages: 6
                Product

                SciELO Spain

                Categories
                Artículo Especial

                anemia,quality of life,Transfusión sanguínea,palliative care,cuidados paliativos,calidad de vida,Blood transfusion

                Comments

                Comment on this article